Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/109 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME15855241
PMID: | 15855241
LR: | 20061013
CED: | 20050517
DCO: | 20060302
Autoren: | Poolsup N; Suthisisang C; Channark P; Kittikulsuth W
Titel: | Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials.
Quelle: | The Annals of pharmacotherapy; VOL: 39 (6); p. 1080-7 /200506/
PM: | Print-Electronic
EPD: | 20050426
SU: | IM
Sprache: | English
CY: | United States
JID: | 9203131
ISSN: | 1060-0280
CO: | APHRER
Institution: | Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon-Pathom, Thailand. nalinee@email.pharm.su.ac.th
DT: | Journal Article; Meta-Analysis; Review
RN: | 45
Schlagwörter
CT: | DISEASE PROGRESSION; GLUCOSAMINE/administration & dosage; GLUCOSAMINE/adverse effects; GLUCOSAMINE/*therapeutic use; HUMANS; OSTEOARTHRITIS, KNEE/*drug therapy; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME
CTG: | KRANKHEITSPROGRESSION; GLUCOSAMIN/Verabreichung & Dosierung; GLUCOSAMIN/unerwünschte Nebenwirkungen; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; RANDOMISIERTE KONTROLLIERTE STUDIEN; ZEITFAKTOREN; BEHANDLUNGSERGEBNIS
TE: | Glucosamine/3416-24-8
CR: | 3416-24-8
AB: | OBJECTIVE: To investigate the structural and symptomatic efficacy and safety of glucosamine in knee osteoarthritis (OA). DATA SOURCES: Clinical trials of glucosamine were identified through electronic searches (MEDLINE, EMBASE, BIOSIS, EMB review, the Cochrane Library) using the key words glucosamine, osteoarthritis, degenerative joint disease, degenerative arthritis, osteoarthrosis, gonarthrosis, knee, disease progression, and clinical trial. The bibliographic databases were searched from their respective inception dates to August 2004. We also hand-searched reference lists of relevant articles. STUDY SELECTION AND DATA EXTRACTION: Studies were included if they were double-blind, randomized, controlled trials that evaluated oral glucosamine long-term treatment in knee OA; lasting at least one year; and reporting as outcome measures the symptom severity and disease progression as assessed by joint space narrowing. Two authors interpreted data independently. Disagreements were resolved through discussion. DATA SYNTHESIS: Glucosamine sulfate was more effective than placebo in delaying structural progression in knee OA. The risk of disease progression was reduced by 54% (pooled RR 0.46; 95% CI 0.28 to 0.73; p = 0.0011). The number-needed-to-treat was 9 (95% CI 6 to 20). The pooled effect sizes for pain reduction and improvement in physical function were 0.41 (95% CI 0.21 to 0.60; p < 0.0001) and 0.46 (95% CI 0.27 to 0.66; p < 0.0001), respectively, in favor of glucosamine sulfate. Glucosamine sulfate caused no more adverse effects than placebo. CONCLUSIONS: The available evidence suggests that glucosamine sulfate may be effective and safe in delaying the progression and improving the symptoms of knee OA. Due to the sparse data on structural efficacy and safety, further studies are warranted.

» Volltext »
» Fenster schließen »